“…Recently, a series of THR antagonists have been identified that inhibit THR-coactivator interaction by binding to the AF-2 domain (Arnold et al ., 2005; Arnold et al ., 2006; Arnold et al ., 2007a; Arnold et al ., 2007b; Estebanez-Perpina et al ., 2007a; Hwang et al ., 2009; Hwang et al ., 2011; Hwang et al ., 2012; Hwang et al ., 2013). These compounds may be useful to treat metabolic disorders and hyperthyroidism without affecting thyroid hormone levels; however additional studies revealed significant dose-related cardiotoxicity, suspected to arise from ion-channel inhibition(Arnold et al ., 2005; Arnold et al ., 2006; Arnold et al ., 2007a; Arnold et al ., 2007b; Estebanez-Perpina et al ., 2007a; Hwang et al ., 2009; Hwang et al ., 2011; Hwang et al ., 2012; Hwang et al ., 2013).…”